File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Development of vaccines and passive immunotherapy against SARS coronavirus using mouse and SCID-PBL/hu mouse models

TitleDevelopment of vaccines and passive immunotherapy against SARS coronavirus using mouse and SCID-PBL/hu mouse models
Authors
Issue Date2006
PublisherSpringer New York LLC.
Citation
Advances In Experimental Medicine And Biology, 2006, v. 581, p. 561-566 How to Cite?
AbstractWe have investigated novel vaccines strategies against severe acute respiratory syndrome (SARS) CoV infection using cDNA constructs encoding the structural antigens; spike (S), membrane (M), envelope (E), or nucleocapsid (N) protein, derived from SARS CoV (strain HKU39849, TW1, or FFM-1). As SARS-CoV is thought to infect the alveolar epithelial cell of the lung,in the present study, a type II alveolar epithelial cell clone, T7, was used to analyze the mechanism of CTL against SARS CoV membrane antigens. Mice vaccinated with SARS CoV (N) DNA or (M) DNA using pcDNA 3.1(+) plasmid vector showed T-cell immune responses (CTL induction and proliferation) against type II alveolar epithelial cells (T7) transfected with SARS (N) or (M) DNA, respectively. To determine whether these DNA vaccines could induce T-cell immune responses in humans as well as in mice, SCID-PBL/hu mice were immunized with these DNA vaccines. PBL from healthy human volunteers were administered i.p. into IL-2 receptor γ-chain-disrupted NOD-SCID mice [IL-2R(-/-) NOD-SCID]. SCID-PBL/hu mice thus constructed can be used to analyze the human immune response in vivo. The SCID-PBL/hu mice were immunized with SARS (N) DNA or (M) DNA and analyzed for a human T-cell immune response. The M DNA vaccine enhanced CTL activity and proliferation in the presence of M peptide in SCID-PBL/hu mice. Furthermore, the SARS N DNA vaccine induced CTL activity (IFN-γ production by recombinant N protein or N protein-pulsed autologous B blast cells) and proliferation of spleen cells in SCID-PBL/hu mice. These results, demonstrate that SARS M and N DNA vaccines induced human CTL and human T-cell proliferative responses. On the other hand, we have developed SARS DNA vaccines that induce human neutralizing antibodies and human monoclonal antibodies against SARS CoV. Transgenic mice expressing SARS-CoV receptor (angiotensin converting enzyme 2) are also under development. These vaccines are expected to induce immune responses specific for SARS CoV in human and should provide useful tool for development of protective vaccines.
Persistent Identifierhttp://hdl.handle.net/10722/79029
ISSN
2015 Impact Factor: 1.953
2015 SCImago Journal Rankings: 0.887
References

 

DC FieldValueLanguage
dc.contributor.authorOkada, Men_HK
dc.contributor.authorTakemoto, Yen_HK
dc.contributor.authorOkuno, Yen_HK
dc.contributor.authorHashimoto, Sen_HK
dc.contributor.authorFukunaga, Yen_HK
dc.contributor.authorTanaka, Ten_HK
dc.contributor.authorKita, Yen_HK
dc.contributor.authorKuwayama, Sen_HK
dc.contributor.authorMuraki, Yen_HK
dc.contributor.authorKanamaru, Nen_HK
dc.contributor.authorTakai, Hen_HK
dc.contributor.authorOkada, Cen_HK
dc.contributor.authorSakaguchi, Yen_HK
dc.contributor.authorFurukawa, Ien_HK
dc.contributor.authorYamada, Ken_HK
dc.contributor.authorIzumiya, Men_HK
dc.contributor.authorYoshida, Sen_HK
dc.contributor.authorMatsumoto, Men_HK
dc.contributor.authorKase, Ten_HK
dc.contributor.authorPeiris, JSMen_HK
dc.contributor.authorDeMello, DEen_HK
dc.contributor.authorChen, PJen_HK
dc.contributor.authorYamamoto, Nen_HK
dc.contributor.authorYoshinaka, Yen_HK
dc.contributor.authorNomura, Ten_HK
dc.contributor.authorIshida, Ien_HK
dc.contributor.authorMorikawa, Sen_HK
dc.contributor.authorTashiro, Men_HK
dc.contributor.authorSakatani, Men_HK
dc.date.accessioned2010-09-06T07:49:44Z-
dc.date.available2010-09-06T07:49:44Z-
dc.date.issued2006en_HK
dc.identifier.citationAdvances In Experimental Medicine And Biology, 2006, v. 581, p. 561-566en_HK
dc.identifier.issn0065-2598en_HK
dc.identifier.urihttp://hdl.handle.net/10722/79029-
dc.description.abstractWe have investigated novel vaccines strategies against severe acute respiratory syndrome (SARS) CoV infection using cDNA constructs encoding the structural antigens; spike (S), membrane (M), envelope (E), or nucleocapsid (N) protein, derived from SARS CoV (strain HKU39849, TW1, or FFM-1). As SARS-CoV is thought to infect the alveolar epithelial cell of the lung,in the present study, a type II alveolar epithelial cell clone, T7, was used to analyze the mechanism of CTL against SARS CoV membrane antigens. Mice vaccinated with SARS CoV (N) DNA or (M) DNA using pcDNA 3.1(+) plasmid vector showed T-cell immune responses (CTL induction and proliferation) against type II alveolar epithelial cells (T7) transfected with SARS (N) or (M) DNA, respectively. To determine whether these DNA vaccines could induce T-cell immune responses in humans as well as in mice, SCID-PBL/hu mice were immunized with these DNA vaccines. PBL from healthy human volunteers were administered i.p. into IL-2 receptor γ-chain-disrupted NOD-SCID mice [IL-2R(-/-) NOD-SCID]. SCID-PBL/hu mice thus constructed can be used to analyze the human immune response in vivo. The SCID-PBL/hu mice were immunized with SARS (N) DNA or (M) DNA and analyzed for a human T-cell immune response. The M DNA vaccine enhanced CTL activity and proliferation in the presence of M peptide in SCID-PBL/hu mice. Furthermore, the SARS N DNA vaccine induced CTL activity (IFN-γ production by recombinant N protein or N protein-pulsed autologous B blast cells) and proliferation of spleen cells in SCID-PBL/hu mice. These results, demonstrate that SARS M and N DNA vaccines induced human CTL and human T-cell proliferative responses. On the other hand, we have developed SARS DNA vaccines that induce human neutralizing antibodies and human monoclonal antibodies against SARS CoV. Transgenic mice expressing SARS-CoV receptor (angiotensin converting enzyme 2) are also under development. These vaccines are expected to induce immune responses specific for SARS CoV in human and should provide useful tool for development of protective vaccines.en_HK
dc.languageengen_HK
dc.publisherSpringer New York LLC.en_HK
dc.relation.ispartofAdvances in Experimental Medicine and Biologyen_HK
dc.titleDevelopment of vaccines and passive immunotherapy against SARS coronavirus using mouse and SCID-PBL/hu mouse modelsen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0065-2598&volume=581&spage=561&epage=6&date=2006&atitle=Development+of+vaccines+and+passive+immunotherapy+against+SARS+coronavirus+using+mouse+and+SCID-PBL/hu+mouse+modelsen_HK
dc.identifier.emailPeiris, JSM: malik@hkucc.hku.hken_HK
dc.identifier.authorityPeiris, JSM=rp00410en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/978-0-387-33012-9-102en_HK
dc.identifier.scopuseid_2-s2.0-39049179416en_HK
dc.identifier.hkuros136341en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-39049179416&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume581en_HK
dc.identifier.spage561en_HK
dc.identifier.epage566en_HK
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridOkada, M=8247382100en_HK
dc.identifier.scopusauthoridTakemoto, Y=35238734900en_HK
dc.identifier.scopusauthoridOkuno, Y=7202193504en_HK
dc.identifier.scopusauthoridHashimoto, S=8208749500en_HK
dc.identifier.scopusauthoridFukunaga, Y=23496339500en_HK
dc.identifier.scopusauthoridTanaka, T=7406729675en_HK
dc.identifier.scopusauthoridKita, Y=35237454300en_HK
dc.identifier.scopusauthoridKuwayama, S=23497612100en_HK
dc.identifier.scopusauthoridMuraki, Y=8247380200en_HK
dc.identifier.scopusauthoridKanamaru, N=8247380300en_HK
dc.identifier.scopusauthoridTakai, H=8247380400en_HK
dc.identifier.scopusauthoridOkada, C=23498601500en_HK
dc.identifier.scopusauthoridSakaguchi, Y=8247380600en_HK
dc.identifier.scopusauthoridFurukawa, I=36742646100en_HK
dc.identifier.scopusauthoridYamada, K=35239179400en_HK
dc.identifier.scopusauthoridIzumiya, M=23496640400en_HK
dc.identifier.scopusauthoridYoshida, S=35458480200en_HK
dc.identifier.scopusauthoridMatsumoto, M=7404939861en_HK
dc.identifier.scopusauthoridKase, T=7005279800en_HK
dc.identifier.scopusauthoridPeiris, JSM=7005486823en_HK
dc.identifier.scopusauthoridDeMello, DE=7006546651en_HK
dc.identifier.scopusauthoridChen, PJ=7408354514en_HK
dc.identifier.scopusauthoridYamamoto, N=7403608342en_HK
dc.identifier.scopusauthoridYoshinaka, Y=7003532886en_HK
dc.identifier.scopusauthoridNomura, T=54409213700en_HK
dc.identifier.scopusauthoridIshida, I=18344116900en_HK
dc.identifier.scopusauthoridMorikawa, S=7102226341en_HK
dc.identifier.scopusauthoridTashiro, M=7201482415en_HK
dc.identifier.scopusauthoridSakatani, M=7006692689en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats